The Senate Finance Committee today held a on strategies to reduce prescription drug costs and encourage innovation and competition in the market. Health and Human Services Secretary Alex Azar testified on the administration’s blueprint to lower drug prices, released in May. In a statement submitted to the committee, AHA urged Congress to pass the Creating and Restoring Equal Access to Equivalent Samples Act to prevent anticompetitive behaviors used to block and delay entry of generic drugs; and H.R. 4392 to prevent a 30% reduction in Medicare payment to certain hospitals for outpatient drugs purchased under the 340B drug savings program, among other actions. Hospital spending on inpatient drugs increased 38.7% per admission between 2013 and 2015, more than three times the increase in spending for retail prescription drugs over the period, the statement notes.

Related News Articles

Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and…
Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District…
Headline
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that…
Headline
The Department of Health and Human Services Jan. 17 announced 15 Medicare Part D drugs selected for the latest round of price negotiations. Negotiations will…
Headline
Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, according to a report released Jan. 9 by…